Dimethyl fumarate in relapsing-remitting multiple sclerosis: Rationale, mechanisms of action, pharmacokinetics, efficacy and safety

Expert Review of Neurotherapeutics

Volumn 15, Issue 4, 2015, Pages 339-346

  Dubey, Duvyanshu ^a   Kieseier, Bernd C ^b   Hartung, Hans P ^b   Hemmer, Bernhard ^c   Warnke, Clemens ^b   Menge, Til ^b   Miller Little, William A ^a   Stuve, Olaf ^a,c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

dimethyl fumarate; experimental autoimmune encephalomyelitis; immunology; multiple sclerosis; pharmacology

Indexed keywords

DNA; FUMARIC ACID DIMETHYL ESTER; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROTEIN BCL 2; TRANSCRIPTION FACTOR NRF2; VASCULOTROPIN RECEPTOR 2; ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADAPTIVE IMMUNITY; ANTIPROLIFERATIVE ACTIVITY; CITRIC ACID CYCLE; DIARRHEA; DNA FRAGMENTATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ENTERITIS; EOSINOPHILIA; EXHALATION; FATIGUE; FLUSHING; FOOD DRUG INTERACTION; G2 PHASE CELL CYCLE CHECKPOINT; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTRANSAMINASEMIA; INFLUENZA; INNATE IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NAUSEA; NEUROPROTECTION; NONHUMAN; NUCLEAR IMPORT; OXIDATION REDUCTION POTENTIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; UPREGULATION; URINARY EXCRETION; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION; VOMITING; CHEMISTRY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ANTI-INFLAMMATORY AGENTS; DIMETHYL FUMARATE; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84925846204     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1025755     Document Type: Review

References (60)

1. Ghoreschi K, Bruck J, Kellerer C, et al.Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells.J Exp Med 2011; 208: 2291-303
2. Meissner M, Valesky EM, Kippenberger S, Kaufmann R.Dimethyl fumarate - only an anti-psoriatic medication?.J Dtsch Dermatol Ges 2012; 10: 793-801
3. Schweckendiek W.[Treatment of psoriasis vulgaris].Med Monatsschr 1959; 13: 103-4
4. Loleit V, Biberacher V, Hemmer B.Current and future therapies targeting the immune system in multiple sclerosis.Curr Pharm Biotechnol 2014; 15(3): 276-96
5. FDA approves new multiple sclerosis treatment: Tecfidera.Available from: http://.www.fda.gov/NewsEvents/Newsroom/.PressAnnouncements/ucm345528.htm [Accessed 28 March 2013
6. Killestein J, Rudick RA, Polman CH.Oral treatment for multiple sclerosis.Lancet Neurol 2011; 10: 1026-34
7. Anderson DW, Ellenberg JH, Leventhal CM, et al.Revised estimate of the prevalence of multiple sclerosis in the United States.Ann Neurol 1992; 31: 333-6
8. Alonso A, Hernan MA.Temporal trends in the incidence of multiple sclerosis: a systematic review.Neurology 2008; 71: 129-35
9. Hirtz D, Thurman DJ, Gwinn-Hardy K, et al.How common are the "common" neurologic disorders?.Neurology 2007; 68: 326-37
10. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG.Multiple sclerosis.N Engl J Med 2000; 343: 938-52
11. Barcellos LF, Oksenberg JR, Begovich AB, et al.HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course.Am J Hum Genet 2003; 72: 710-16
12. Gocke AR, Cravens PD, Ben LH, et al.T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity.J Immunol 2007; 178: 1341-8
13. Mosmann TR, Sad S.The expanding universe of T-cell subsets: th1, Th2 and more.Immunol Today 1996; 17: 138-46
14. Chitnis T.The role of CD4 T cells in the pathogenesis of multiple sclerosis.Int Rev Neurobiol 2007; 79: 43-72
15. Fillatreau S, Sweenie CH, McGeachy MJ, et al.B cells regulate autoimmunity by provision of IL-10.Nat Immunol 2002; 3: 944-50
16. Hauser SL, Waubant E, Arnold DL, et al.B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.N Engl J Med 2008; 358: 676-88
17. Weber MS, Prod'homme T, Youssef S, et al.Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.Nat Med 2007; 13: 935-43
18. Lee DH, Gold R, Linker RA.Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters.Int J Mol Sci 2012; 13: 11783-803
19. Salmen A, Gold R.Mode of action and clinical studies with fumarates in multiple sclerosis.Exp Neurol 2014; 262(Pt A): 52-6
20. Lin SX, Lisi L, Dello RC, et al.The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1.ASN Neuro 2011; 3
21. Hollins DL, Suliman HB, Piantadosi CA, Carraway MS.Glutathione regulates susceptibility to oxidant-induced mitochondrial DNA damage in human lymphocytes.Free Radic Biol Med 2006; 40: 1220-6
22. Treumer F, Zhu K, Glaser R, Mrowietz U.Dimethylfumarate is a potent inducer of apoptosis in human T cells.J Invest Dermatol 2003; 121: 1383-8
23. Bureau F, Vanderplasschen A, Jaspar F, et al.Constitutive nuclear factor-kappaB activity preserves homeostasis of quiescent mature lymphocytes and granulocytes by controlling the expression of distinct Bcl-2 family proteins.Blood 2002; 99: 3683-91
24. Ghods AJ, Glick R, Braun D, Feinstein D.Beneficial actions of the anti-inflammatory dimethyl fumarate in glioblastomas.Surg Neurol Int 2013; 4: 160
25. Odom RY, Dansby MY, Rollins-Hairston AM, et al.Phytochemical induction of cell cycle arrest by glutathione oxidation and reversal by N-Acetylcysteine in human colon carcinoma cells.Nutr Cancer 2009; 61: 332-9
26. Loewe R, Valero T, Kremling S, et al.Dimethylfumarate impairs melanoma growth and metastasis.Cancer Res 2006; 66: 11888-96
27. Milligan SA, Nopajaroonsri C.Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro.Anticancer Res 2001; 21: 39-44
28. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr.Control of inducible chemoresistance: enhanced anti-Tumor therapy through increased apoptosis by inhibition of NF-kappaB.Nat Med 1999; 5: 412-17
29. Meissner M, Doll M, Hrgovic I, et al.Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-Angiogenic action.J Invest Dermatol 2011; 131: 1356-64
30. di Nuzzo L, Orlando R, Nasca C, Nicoletti F.Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.Drug Des Devel Ther 2014; 8: 555-68
31. Peng H, Guerau-de-Arellano M, Mehta VB, et al.Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-Activated kinase 1 (MSK1) signaling.J Biol Chem 2012; 287: 28017-26
32. Schilling S, Goelz S, Linker R, et al.Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration.Clin Exp Immunol 2006; 145: 101-7
33. de Jong R, Bezemer AC, Zomerdijk TP, et al.Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate.Eur J Immunol 1996; 26: 2067-74
34. Ghoreschi K, Mrowietz U, Rocken M.A molecule solves psoriasis?.Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses.J Mol Med (Berl) 2003; 81: 471-80
35. Loewe R, Pillinger M, de Martin R, et al.Dimethylfumarate inhibits tumor-necrosisfactor-induced CD62E expression in an NF-kappa B-dependent manner.J Invest Dermatol 2001; 117: 1363-8
36. Loewe R, Holnthoner W, Groger M, et al.Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells.J Immunol 2002; 168: 4781-7
37. Scannevin RH, Chollate S, Jung MY, et al.Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway.J Pharmacol Exp Ther 2012; 341: 274-84
38. Linker RA, Lee DH, Ryan S, et al.Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.Brain 2011; 134: 678-92
39. Kapturczak MH, Wasserfall C, Brusko T, et al.Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse.Am J Pathol 2004; 165: 1045-53
40. Albrecht P, Lewerenz J, Dittmer S, et al.Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xcas a neuroprotective drug target.CNS Neurol Disord Drug Targets 2010; 9: 373-82
41. Frohman EM, Racke MK, Raine CS.Multiple sclerosis-The plaque and its pathogenesis.N Engl J Med 2006; 354: 942-55
42. Nicholas JA, Boster AL, Imitola J, et al.Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.Drug Des Devel Ther 2014; 8: 897-908
43. Venci JV, Gandhi MA.Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis.Ann Pharmacother 2013; 47: 1697-702
44. Sheikh SI, Nestorov I, Russell H, et al.Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.Clin Ther 2013; 35: 1582-94
45. Kappos L, Gold R, Miller DH, et al.Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.Lancet 2008; 372: 1463-72
46. Gold R, Kappos L, Arnold DL, et al.Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.N Engl J Med 2012; 367: 1098-107
47. Kurtzke JF.Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology 1983; 33: 1444-52
48. Fox RJ, Miller DH, Phillips JT, et al.Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.N Engl J Med 2012; 367: 1087-97
49. Havrdova E, Hutchinson M, Kurukulasuriya NC, et al.Oral BG-12 (dimethyl fumarate.for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM.Evaluation of: Gold R, Kappos L, Arnold D, et al.Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.N Engl J Med 2012; 367: 1098-107; and Fox RJ, Miller DH, Phillips JT, et al.Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.N Engl J Med 2012; 367: 1087-97.Expert Opin Pharmacother 2013; 14: 2145-56
50. Mrowietz U, Christophers E, Altmeyer P.Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use.The German Fumaric Acid Ester Consensus Conference.Br J Dermatol 1999; 141: 424-9
51. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN.Long-Term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.Br J Dermatol 2003; 149: 363-9
52. Russell H, O'Gorman J, Li J, et al.BG-12 (Dimethyl Fumarate) with aspirin pretreatment or slow dose titration.[Accessed 30 May 2014
53. Phillips JT, Erwin A, Agrella S, et al.A Delphi panel to address management of gastrointestinal side effects observed with use of delayed-release dimethyl fumarate.[Accessed 29 May 2014
54. Ermis U, Weis J, Schulz JB.PML in a patient treated with fumaric acid.N Engl J Med 2013; 368: 1657-8
55. Sweetser MT, Dawson KT, Bozic C.Case reports of PML in patients treated for psoriasis.N Engl J Med 2013; 369: 1082
56. van Oosten BW, Killestein J, Wattjes MP.Case reports of PML in patients treated for psoriasis.N Engl J Med 2013; 369: 1081-2
57. Sweetser MT, Dawson KT, Bozic C.Manufacturer's response to case reports of PML.N Engl J Med 2013; 368: 1659-61
58. Molloy ES, Calabrese LH.Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.Arthritis Rheum 2012; 64: 3043-51
59. MS Trust.PML case reported for dimethyl fumarate (Tecfidera).Available from: http://.www.mstrust.org.uk/news/article.jsp?id=6542 [Accessed 23 October 2014
60. Tirrell M.Biogen Boosts 2013 Forecast as Tecfidera Tops Estimates.Available from: http://www.bloomberg.com/news/articles/.2013-10-28/biogen-boosts-2013-forecast-Astecfidera-Tops-estimates [Accessed 28 October 2013